Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Radiopharm Theranostics Limited ( (AU:RAD) ) has shared an announcement.
Radiopharm Theranostics Limited announced positive clinical updates across four of its programs, highlighting significant advancements in its pipeline. The company reported promising preliminary data from its Phase 2b imaging clinical trial of RAD 101, Phase 1 trials of RAD 202 and RAD 204, and a Phase 1 study of RAD 301, all showing potential in targeting various cancer types. These developments underscore the company’s strategic execution and commitment to advancing its clinical programs, with expectations for further data readouts and trial progressions in the near term.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need. The company is dedicated to transforming cancer care through potentially first-in-class and best-in-class radiopharmaceuticals.
Average Trading Volume: 4,552,171
Technical Sentiment Signal: Buy
Current Market Cap: A$87.5M
Learn more about RAD stock on TipRanks’ Stock Analysis page.